title: Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.
abstract: BACKGROUND
  Prognostic factors have been shown to be important when stratifying patients with prostate cancer into randomized trials and counseling the individual patient regarding his chances of response to treatment. However, there are no reports on prognostic factors in patients with Stage D2 prostate cancer treated with a pure antiandrogen as monotherapy.
  
  
  METHODS
  The authors studied a variety of possible prognostic factors among 150 patients with metastatic prostate cancer treated with an antiandrogen (Casodex, Imperial Chemical Industries, Wilmington, DE).
  
  
  RESULTS
  In a univariate analysis, performance status; extent of disease (EOD); pretreatment hemoglobin, alkaline phosphatase, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP) levels; and extent of disease (EOD) on bone scan all were found to be significant prognostic factors (P < 0.05). Pretreatment serum testosterone levels, identified as one of the most important prognostic factors, was not identified as significant in the current study.
  
  
  CONCLUSIONS
  Although the pretreatment testosterone level was shown to be an important prognostic factor in previous studies, using other modes of androgen ablation (reducing testosterone to below castrate levels), the current study suggest it may not be a helpful factor if the therapy used is antiandrogens as monotherapy. This may relate to the different mode of action of antiandrogens, which do not reduce serum testosterone levels.
authors.affiliation: Department of Urology, University of Miami School of Medicine, FL 33101.
authors.forename: H
authors.initials: H
authors.lastname: Matzkin
authors.forename: M S
authors.initials: MS
authors.lastname: Soloway
authors.forename: P F
authors.initials: PF
authors.lastname: Schellhammer
authors.forename: G
authors.initials: G
authors.lastname: Chodak
authors.forename: J A
authors.initials: JA
authors.lastname: Smith
authors.forename: R
authors.initials: R
authors.lastname: Caplan
authors.forename: G T
authors.initials: GT
authors.lastname: Kennealey
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009570:Nitriles; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014105:Tosyl Compounds
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide